Clay Siegall, Ph. D. is the founder of a leading company dedicated to medical research – Seattle Genetics. He worked for about a decade at the Bristol – Myers Squibb Pharmaceutical Research Institute before he moved on to take a position at the National Cancer Institute. Dr Clay Siagall founded his company Seattle Genetics in 1988. He works as the President and Chief Executive Officer of the esteemed company.
Seattle Genetics developed a medication which was approved by the U. S. Food and Drugs Association in 2011. The first ADC is now available on the drug market in more than seventy countries all around the world. Clay Siegall, Ph. D. is the owner of more than ten patents, and some of them have been launched on the market and have been made widely available to the public.
Clay Siegall, Ph. D. decided to establish his company Seattle Genetics because he wanted to contribute as much as possible could to the research against cancer. He views the medical science of oncology as one of the most crucial ones in the world of medicine. Cancer, however, has many types and some of them have been studied too little. There is nowhere near enough data collected of breast cancer, for example. Clay Siegall, Ph. D. wanted to improve the tools that were already available to oncologists both for research purposes and for treating the patients.
Clay Siegall, Ph. D. is the author of more than seventy articles on the topics of medicine, research against cancer, and the process of establishing a company. His advice to young entrepreneurs is to learn as much as possible. He advises them to never pass up on an opportunity to learn from those who are more experienced than they are because the key to success is closely related to knowing your field well enough.
Seattle Genetics and Dr Clay Siegall have made great contributions to the medical field. Dr Clay Siegall has also done philanthropy work, and he also doubles as a teacher at a university. He has given a large number of seminars and has spoken at many medical events all around the world.